• 제목/요약/키워드: Doxorubicin

검색결과 340건 처리시간 0.023초

배양산삼 추출액의 Doxorubicin 독성 완화 효과 (Protective Effect of the Water Extract of Tissue Cultured Root of Wild Ginseng Against Doxorubicin Toxicity)

  • 최경운;이평재;김호현
    • 대한본초학회지
    • /
    • 제24권3호
    • /
    • pp.13-19
    • /
    • 2009
  • Objectives : This study was aimed to define the protective effect of Tissue Cultured Root of Wild Ginseng (CWG) against doxorubicin (Doxo) toxicity, and investigate the anti-tumor synergic effect of CWG in combination with Doxo in tumor-bearing C57BL/6 mice. Methods : Tumor-bearing mice were established by single inoculation with B16/F10 melanoma cells (2$\times$10$^6$/ml) subcutaneously. Tumor-bearing mice (tumor volume between 50-100 mm$^3$) were selected and divided them into control, Doxo, and Doxo+CWG group. Mice of Doxo group were received with Doxo (4 mg/kg of B.W.) intraperitoneally at 0, 4, 8 days after starting the experiment. Mice of Doxo+CWG group were received CWG water extract during 12 days in combination with Doxo treatment. The body weight, tumor volume, tumor weight, and organ weight (heart, liver, kidney, and testis) were measured. And serum SPK, GOT and creatinine values were analysed. Results : The volume and weights of tumor masses in Doxo group were decreased significantly compared with the those of control group. And the those of Doxo+CWG group were not significantly different from the those of Doxo group. Whereas the weight of body, liver, kidney and testis in Doxo+CWG group were increased significantly compared with the those of Doxo group. The level of serum CPK and GOT in Doxo group were increased compared with the those of control group. But the value of Doxo+CWG group were decreased significantly compared with the values of Doxo group. Conclusions : These results suggest that CWG has protective effect against doxorubicin toxicity. And these effect is guessed that is caused in augmentation of vital energy.

Characterization of Doxorubicin-nonproducing Mutant, Nu3 of Streptomyces peucetius ATCC27952

  • Kyu, Hwang-Cheol;Lee, Hong-Sub;Hong, Young-Soo;Paek, Nam-Soo;Kim, Tae-Han;Lee, Jung-Joon
    • Journal of Microbiology and Biotechnology
    • /
    • 제7권5호
    • /
    • pp.363-366
    • /
    • 1997
  • A doxorubicin-nonproducing mutant, Nu23 was selected from the mutagenesis of Streptomyces peucetius ATCC27952. Chemical and molecular biological analysis suggested that the mutant was blocked at the step between polyketide synthase and aklaviketon reductase in the biosynthesis of doxorubicin. Furthermore, the bioconversion experiment with the mutant revealed that 13-dihydrodaunorubicin is likely to be a biosynthetic intermediate.

  • PDF

Synthesis of New Anthracycline Derivatives Containing Lactic or Stearic Acid Moiety

  • Rho, Young S.;Kim, Wan-Joong;Yoo, Dong-Jin
    • Bulletin of the Korean Chemical Society
    • /
    • 제27권9호
    • /
    • pp.1359-1363
    • /
    • 2006
  • Novel anthracycline analogues 2-9 as potential anticancer agents were synthesized from daunomycin (1a) and doxorubicin (1b). Compounds 2, 6, and 7 were prepared by the nucleophilic displacement type esterification of a 14-bromodaunomycin (1c) with a sodium lactate, and stearic acid, respectively. Compounds 3-5 and 7-9 were prepared by the reaction of either daunomycin (1a) or doxorubicin (1b) with L-lactic and stearic acids in the presence of EDCI/PP reagents.

Synthesis and Antitumor Activity of New Anthracycline Analogues

  • ;김완중;유동진;강현수;장순량
    • Bulletin of the Korean Chemical Society
    • /
    • 제22권9호
    • /
    • pp.963-968
    • /
    • 2001
  • New anthracycline analogues 2-9 as potential anticancer agents have been synthesized from daunomycin (1a) and doxorubicin (1b). Compounds 2 and 6 were prepared by the nucleophilic displacement type esterification of 14-bromodaunomycin (1c) with N-benzoyl-(2R,3S)-phenylisoserine and L-pyroglutamic acid in triethyl-amine, respectively. Compounds 3, 7 and 4, 8 were prepared by the reaction of either daunomycin (1a) or doxorubicin (1b) with one equivalent of the corresponding acids in the presence of EDCI/PP. Compounds 5, 9 were obtained from 1b by reaction with 2.2 equivalents of the corresponding acids in the same manner. The cytotoxic activities of the analogues in comparison with adrimycin on cultured SNU-16 and MCF7 cell were described.

Chemotherapy of Mammary Comedocarcinoma with Doxorubicin in a Dog

  • Kim, Yeonsoo;Seo, Kyoungwon;Song, Kunho
    • 한국임상수의학회지
    • /
    • 제38권6호
    • /
    • pp.274-278
    • /
    • 2021
  • An 11-year-old, intact female, Miniature Poodle presented with an abdominal mass. The abdominal mass was located around the right fifth mammary gland. The surgically removed mammary mass was subjected to histopathological examination. Based on the microscopic interpretation, a final diagnosis of an intermediate grade infiltrative mammary comedocarcinoma was established. Computed tomography for metastasis evaluation after surgical resection of the tumor showed enlarged right medial iliac and right inguinal lymph nodes, and a micronodule in the accessory lung lobe, suggesting metastasis of the mammary gland tumor. Doxorubicin, a chemotherapeutic drug, was administered six times at three week intervals. However, despite chemotherapy, the masses around the fourth and fifth mammary gland on the right side enlarged in size, and the treatment was discontinued at the request of the owner. The anticancer response to mammary comedocarcinoma is poor and the patient is in hospice management. This is the first attempt to treat a case of canine mammary comedocarcinoma in South Korea.

Doxorubicin-loaded PEI-silica Nanoparticles for Cancer Therapy

  • Heekyung Park;Seungho Baek;Donghyun Lee
    • Korean Chemical Engineering Research
    • /
    • 제61권4호
    • /
    • pp.570-575
    • /
    • 2023
  • Targeted anticancer drug delivery systems are needed to enhance therapeutic efficacy by selectively delivering drugs to tumor cells while minimizing off-target effects, improving treatment outcomes and reducing toxicity. In this study, a silica-based nanocarrier capable of targeting drug delivery to cancer cells was developed. First, silica nanoparticles were synthesized by the Stöber method using the surfactant cetyltrimethylammonium bromide (CTAB). Increasing the ratio of EtOH in the solvent produced uniformly spherical silica nanoparticles. Washing the nanoparticles removed unreacted residues, resulting in a non-toxic carrier for drug delivery in cells. Upon surface modification, the pH-responsive polymer, polyethyleneimine (PEI) exhibited slow doxorubicin release at pH 7.4 and accelerated release at pH 5.5. By exploiting this feature, we developed a system capable of targeted drug release in the acidic tumor microenvironment.

마우스 혈장과 조직에서의 doxorubicin 측정 HPLC-MS/MS 방법 (Validation of a HPLC MS/MS Method for Determination of Doxorubicin in Mouse Serum and its Small Tissues)

  • 박정선;김혜경;이혜원;이미현;김현기;채수완;채한정
    • 한국임상약학회지
    • /
    • 제16권1호
    • /
    • pp.23-27
    • /
    • 2006
  • Doxorubicin (DXR) is a type of anti-cancer drug called an 'anthracycline glycoside', It works by impairing DNA synthesis, a crucial feature of cell division, and thus is able to target rapidly dividing cells. Doxorubicin is a very serious anti-cancer medication with definite potential to do great harm as well as great good. A liquid chromatography-tandem mass spectroscopy (LC-MS/MS) method was developed to identify and quantify DXR in small-volume biological samples. After the addition of internal standard (IS, $5{\mu}L\;of\;1{\mu}M/ml$ daunorubicin methanol solution) into the serum sample, the drug and IS were extracted by methanol. Following vortex for a 1min and centrifugation at 15,000g for 10 min the organic phase was transferred and evaporated under a vacuum. The residue was reconstituted with $350{\mu}L$ of mobile phase and $10{\mu}L$ was injected into C18 column with mobile phase composed of 0.05M ammonium acetate (0.1 M acetic acid adjusted to pH 3.5) and acetonitrile (40:60, v/v). The flow rate was kept constant at $350{\mu}L/min$. The ions were quantified in the multiple reaction mode (MRM), using positive ions, on a triple quadrupole mass spectrometer. The lower limits of quantification for Doxorubicin in plasma and small tissues were approximately 0.5 ng/mL and 0.5 ng/mL respectively. Intra- and inter-assay accuracy (% of nominal concentration) and precision (% CV) for all analytes were within 15%, respectively.

  • PDF

PLGA 분자량에 따른 이중층 독소루비신 미립구의 방출거동 (Effect of Molecular Weight of PLGA on Release Behavior of Doxorubicin for Double-Layered PLGA Microspheres)

  • 박정수;양재찬;육순흥;신형식;이종문;김문석;이해방;강길선
    • 폴리머
    • /
    • 제31권3호
    • /
    • pp.189-193
    • /
    • 2007
  • 항암제인 독소루비신의 지속적인 방출을 위하여 PLGA와 독소루비신의 미립구를 수중유형(O/W) 용매증발 방법을 이용하여 약물의 농도와 고분자의 분자량의 변화에 따른 방출거동의 차이를 확인하였다. 이중층 미립구내의 독소루비신의 방출을 분석하기 위하여 형광 분광 광도계를 이용하여 5주 동안 독소루비신의 방출을 보았으며 주사전자현미경을 이용하여 이중층미립구의 단면과 표면을 확인하였다. 제조된 이중층 미립구는 외부층이 전체적으로 매끄러운 표면과 구형을 나타내고 있었고 이중층 미립구의 단면을 잘라 계면층을 중심으로 하여 내부형태와 외부형태를 구분 지을 수 있었다. 또한 제조된 이중층 PLGA 독소루비신 미립구는 방출 결과를 통하여 저분자량의 고분자를 이용할수록 방출이 빠르다는 것을 확인할수 있었다. 따라서 미립구를 제조하는데 있어서 고분자의 분자량을 조절함으로써 방출거동을 조절할 수 있다는 것을 확인하였다.

Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells

  • Putri, Herwandhani;Jenie, Riris Istighfari;Handayani, Sri;Kastian, Ria Fajarwati;Meiyanto, Edy
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권5호
    • /
    • pp.2683-2688
    • /
    • 2016
  • A salt compound of a curcumin analogue, potassium pentagamavunon-0 (K PGV-0) has been synthesized to improve solubility of pentagamavunon-0 which has been proven to have anti-proliferative effects on several cancer cells. The purpose of this study was to investigate cytotoxic activity and metastasis inhibition by K PGV-0 alone and in combination with achemotherapeutic agent, doxorubicin (dox), in breast cancer cells. Based on MTT assay analysis, K PGV-0 showed cytotoxic activity in T47D and 4T1 cell lines with $IC_{50}$ values of $94.9{\mu}M$ and $49.0{\pm}0.2{\mu}M$, respectively. In general, K PGV-0+dox demonstrated synergistic effects and decreased cell viability up to 84.7% in T47D cells and 62.6% in 4T1 cells. Cell cycle modulation and apoptosis induction were examined by flow cytometry. K PGV-0 and K PGV-0+dox caused cell accumulation in G2/M phase and apoptosis induction. Regarding cancer metastasis, while K PGV-0 alone did not show any inhibition of 4T1 cell migration, K PGV-0+dox exerted inhibition. K PGV-0 and its combination with dox inhibited the activity of MMP-9 which has a pivotal role in extracellular matrix degradation. These results show that a combination of K PGV-0 and doxorubicin inhibits cancer cell growth through cell cycling, apoptosis induction, and inhibition of cell migration and MMP-9 activity. Therefore, K PGV-0 may have potential for development as a co-chemotherapeutic agent.